May 15, 2013 | macreportmedia.com
28% Increase in Third Quarter Revenues Over Second Quarter RICHLAND, WA-- May 15, 2013 - ), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer,...
Read more...
IsoRay cancer Cs-131 prostate quarter Cesium lung gyn brachytherapy
May 15, 2013 | medicalxpress.com
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced...
Read more...
All similar articles: 431 »
patient cancer olaparib pancreatic BRCA PARP prostate mutation inhibitor BRCA2 ovarian BRCA1 percent study therapy
May 16, 2013 | healthtipsblogspot.com
Cancer patients are at much greater risk of bankruptcy than people without cancer, according to a large new study. And while the new health care law promises insurance coverage to more than 30 million Americans who lack it now,...
Read more...
All similar articles: 206 »
cancer bankruptcy Literski insurance Himmelstein patient Ramsey health risk Wieckowski coverage prostate
May 16, 2013 | finance.yahoo.com
Shares of Halozyme Therapeutics Inc. climbed Thursday after the company reported clinical trial data for an experimental cancer drug. THE SPARK: Halozyme posted results from an early-stage trial that included ...
Read more...
Halozyme PEGPH20 drug prostate cancer study rise
May 16, 2013 | kfvs12.com
Look for new, improved sunscreen labels Look for new, improved sunscreen labels New labeling laws for sunscreen will help American consumers choose the product that provides the best sun protection, experts say. New labeling...
Read more...
sunscreen cancer label skin Ambien treatment study sun melanoma ovarian drug
May 15, 2013 | streetinsider.com
FREE Breaking News Alerts from StreetInsider.com! Note: This release corresponds to ASCO abstracts 5014, 5004, 5009, 5010, 5013, 5037, 5059, 9617, 9618, 5059, 8502, 7130, 8619, 8613, 8614, 7014, 7056, 7057, 8512 and electronic...
Read more...
 ZYTIGA ibrutinib Janssen abiraterone
May 16, 2013 | kfvs12.com
New drug may help immune system fight cancer New drug may help immune system fight cancer An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other...
Read more...
All similar articles: 78 »
cancer drug immune Pardoll patient study treatment tumor melanoma system PD-L1 fight researcher Ambien
May 16, 2013 | crescent-news.com
DES MOINES, Iowa -- So you didn't win Wednesday's $360 million Powerball jackpot? Make that you and everyone else. A message early Thursday on the multistate lottery's website said the jackpot has soared to $475 million after...
Read more...
All similar articles: 638 »
Powerball jackpot soar prostate ticket winning Medicare Tavenner VA $475 million toilet device cancer sell
May 16, 2013 | cancernetwork.com
A 46-year-old man sought consultation for an abnormal prostate-specific antigen (PSA) level of 9 ng/mL and one prior negative biopsy. Five months ago, while traveling, he had presented to an urgent care facility with a 24-hour...
Read more...
E. David Crawford PSA biopsy PCA3 prostate ConfirmMDx cancer mL ng gland test level TRUS molecular patient TRUS-directed OncoDx
May 17, 2013 | sunherald.com
Psst! Is your hair -- or lack of it -- trying to tell you something? Two new reports link male pattern baldness (not that celebrity-inspired shaved noggin) with higher odds for heart disease and prostate cancer. Those aren't...
Read more...
baldness hairy Signal hair redhead health prostate artery cholesterol skin risk thyroid cancer DHT No. heart LDL
May 16, 2013 | ewallstreeter.com
Screening for and aggressive treatment of prostate cancer has become an enormously lucrative business, if not necessarily a life-saving medical strategy. The minimal media coverage of a recent settlement suggests that at least...
Read more...
kickback prostate bard whistle-blower radiation cancer settlement Darity treatment settle $48.2 million brachytherapy supervisors.'I SettlementAs standards.'Suppression cancer.C.R said.Darity AppearedThe complaint.Her corrected.'In
May 16, 2013 | bioportfolio.com
CHICAGO May 16 2013 PRNewswire &160;Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial...
Read more...
SARIL-RA Genomic Zacks Sanofi Regeneron prostate sarilumab Isis Amgen ASCERTAIN Oncotype patient Blog COMPARE test DX cancer
May 15, 2013 | natures-health-foods.com
Omega 3's Fish-Oil ~ Super Food Remedies Fish-Oil ~ Healing Foods As many of our long time readers know, Marilyn and I are big advocates of adding fish and more specifically, Omega-3's to our diets. A woman’s risk of getting...
Read more...
omega-3 fish-oil DHA omega-6 Bailes fish EPA brain nutrient McGeehin McCloy inflammation omega DRI
May 16, 2013 | medicaldaily.com
After finding out he had prostate cancer just last June, comedian Tommy Chong announces a cancer-free diagnosis that he claims is due to a steady regimen of hash oil. Legendary comedian and noted pot enthusiast Tommy Chong has...
Read more...
All similar articles: 131 »
cancer Chong prostate Tommy cancer-free cure marijuana hash claim Administrationor diagnosis
May 15, 2013 | wakingtimes.com
Waking Times Last June, the famous comedian, actor and pro-marijuana legalization advocate, Tommy Chong, reported to the world that he had been diagnosed with stage 1 prostate cancer and that he was seeking unconventional...
Read more...
Dylan Charles cancer Tommy Chong hemp diet prostate Cannabis treatment oil proper google www.cancer.org legalization
May 15, 2013 | dailyfinance.com
Filed under: Investing Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting -- Exelixis to host investor briefing via live webcast on Sunday, June 2, 2013 SOUTH SAN FRANCISCO, Calif.--(...
Read more...
cabozantinib 8:00-11:45 ASCO Cancer Exelixis Poster Meeting Presentations Abstract Genitourinary Annual Session A2 2013 subsession Featured metastatic Nine NCI-CTEP
May 15, 2013 | prweb.com
Neal Shore, MD, Medical Director, Carolina Urologic Research Center, Myrtle Beach, SC, presented on Vaccine Therapy and Immunotherapy. Daniel Petrylak, MD, Leader, Prostate Medical Oncology at the... (PRWeb May 14, 2013) Read...
Read more...
Audio-Digest urology MD Medical Cancer Medicine 36 Petrylak Center Malignancies Genitourinary Urologic
May 16, 2013 | bayer.com
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013 First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as...
Read more...
o Bayer Abstract Session Poster A2 dichloride Ra-223 III 11:45 regorafenib 8:00 REG Nexavar Cancer ALSYMPCA HealthCare phase oncology S ASCO gastrointestinal Genitourinary Hall
May 16, 2013 | dddmag.com
The U.S. Food and Drug Administration has approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs....
Read more...
All similar articles: 257 »
Xofigo cancer FDA prostate Xtandi approve castration-resistant metastatic testosterone drug
May 16, 2013 | firmenpresse.de
New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research (Thomson Reuters ONE) - Lund, Sweden, May 16, 2013, Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data from...
Read more...
tasquinimod ANYARA Biotech ASCO Active Phase patient renal cancer study Ipsen II treatment mCRPC OS endpoint Meeting
May 17, 2013 | fortmilltimes.com
The Prostate Cancer Foundation (PCF) today announced that it is funding two more Young Investigators (YIs) in China to lead innovative research projects within the country and expand PCF’s global knowledge exchange on...
Read more...
PCF prostate cancer China Young research EMI1 progression
May 16, 2013 | newsfix.ca
Men who drink red wine have a significantly reduced risk of developing prostate cancer, according to a new study. The benefits of moderate consumption of red wine on heart health are well known. A study from the Fred Hutchinson...
Read more...
Abigail Mellier prostate wine cancer red risk reduce flavonoids consumption
May 16, 2013 | ivillage.com
Study found even modest improvements seemed to lower disease risk THURSDAY, May 16 (HealthDay News) -- Men who are physically fit in middle age have a lower risk of developing and dying from certain cancers, new research...
Read more...
All similar articles: 83 »
cancer Lakoski fitness risk colorectal prostate fit treadmill lung Doyle age middle
May 16, 2013 | medicalphysicsweb.org
Photoacoustic imaging can be successfully applied to diagnose prostate cancer – with greater accuracy than the current preferred method, transrectal ultrasound guided biopsy – according to researchers from the US....
Read more...
Photoacoustic prostate transrectal imaging ultrasound cancer Dogra biopsy sample tissue method image
May 17, 2013 | sanfordburnham.org
On May 10, the International Prostate Cancer Foundation awarded Sanford-Burnham's Dr. Ranjan Perera $60,000 to fund a postdoctoral fellow. Dr. Perera and his team's goal is to identify early prognostic markers for prostate cancer.
Read more...
Patrick Bartosch Perera Prostate Sanford-Burnham IPCF Cancer Foundation RNAs marker Nona Dr. International develop Patel molecular test
May 16, 2013 | investegate.co.uk
Algeta ASA : New data and analyses from clinica... Not Intended for US Media Oslo, Norway, 16 May 2013 - Algeta ASA (OSE: ALGETA) announces that further analyses of data subsets from the phase III ALSYMPCA study of the recently...
Read more...
Algeta radium ASA 223 dichloride clinica Ra-223 ALSYMPCA metastasis Xofigo bone CRPC radium-223 Bayer
May 15, 2013 | finanznachrichten.de
RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49th Annual Meeting of the...
Read more...
ibrutinib abstract 8:00am-11:45am mCRPC abiraterone castration-resistant Janssen MD Author Lead Cancer Oncology CDT Genitourinary metastatic acetate poster A2 prostate ASCO session patient USA Ph.D. pts 8:00am-12:00pm leukemia
May 16, 2013 | finanznachrichten.de
Lund, Sweden, 2013-05-16 08:50 CEST (GLOBE NEWSWIRE) -- Lund, Sweden, May 16, 2013, EXINI Diagnostics AB (publ), listed on NASDAQ OMX First North and Active Biotech (NASDAQ OMX NORDIC: ACTI) will p...
Read more...
Globenewswire EXINI Diagnostics BSI AB Biotech tasquinimod Active cancer
May 16, 2013 | finanznachrichten.de
Not Intended for US Media Oslo, Norway, 16 May 2013 - Algeta ASA (OSE: ALGETA) announces that further analyses of data subsets from the phase III ALSYMPCA study of the recently FDA-approved Xofigo® (radium 223 dichloride,...
Read more...
Thomson Algeta radium Xofigo radium-223 223 dichloride ASA Ra-223 ALSYMPCA metastasis bone CRPC Bayer
May 16, 2013 | finanznachrichten.de
CHICAGO, May 16, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial...
Read more...
SARIL-RA Genomic Sanofi Regeneron Zacks prostate Amgen sarilumab ASCERTAIN Oncotype patient Blog COMPARE test DX cancer
